Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma research hub

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

This study is testing a new medicine, WEF-001, for people with advanced cancers that have a specific genetic change called a 'KRAS mutation'. Doctors want to see if it's safe, how the body handles it, and if it could help shrink tumours.